 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Cost-Effectiveness of Screening and Surveillance for Barrett Esophagus
4 February 2003 | Volume 138 Issue 3 | Page I-41
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A Cost–Utility Analysis." It is in the 4 February 2003 issue of Annals of Internal Medicine (volume 138, pages 176-186). The authors are JM Inadomi, R Sampliner, J Lagergren, D Lieberman, AM Fendrick, and N Vakil.
What is the problem and what is known about it so far?
In gastroesopahgeal reflux, stomach contents wash up into the esophagus, causing irritation and indigestion. Over time, GERD can lead to Barrett esophagus, in which intestinal lining replaces the normal lining of the esophagus. People with Barrett esophagus are at increased risk for cancer of the esophagus. The chances of cancer are greatest in patients with Barrett esophagus and dysplasia, a precancerous abnormality of the lining of the esophagus. To diagnose Barrett esophagus, doctors insert a tube with a small camera on the end through patients' mouths into the esophagus, a procedure called endoscopy. Some have proposed that patients with GERD should have endoscopy to screen for Barrett esophagus. Patients with Barrett esophagus would then have periodic endoscopy to find tumors when they are small and treatable. Since reflux is very common, this screening strategy could affect many people and be expensive.
Why did the researchers do this particular study?
To estimate the cost-effectiveness of several strategies of screening for Barrett esophagus.
Who was studied?
Rather than studying actual patients, the researchers used computers to simulate what would happen to a "virtual" group of 50-year-old men with GERD.
How was the study done?
The researchers used published information to estimate what might happen [and how much it would cost] if 50-year-old men with GERD had 1) no screening for Barrett esophagus, 2) screening with periodic endoscopy for patients with Barrett esophagus and no dysplasia, and 3) periodic screening only for patients with Barrett esophagus and dysplasia. They put these estimates into the computer model and calculated how much each strategy would cost per year of life that it saved.
What did the researchers find?
Compared to no screening, the costs of screening with periodic endoscopy of patients with Barrett esophagus and dysplasia were $10,440 per year of life saved. Screening and follow-up of patients without dysplasia every 5 years cost an additional $596,000 per year of life saved.
What were the limitations of the study?
The computer model considers only 50-year-old men, so the results might not apply to other types of patients. The study was a computer simulation, so we cannot be sure what the results would be with actual patients.
What are the implications of the study?
It appears reasonably cost-effective to screen 50-year-old men with GERD for Barrett esophagus, with periodic follow-up endoscopy to detect cancer only for those who have both Barrett esophagus and dysplasia.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. S. Smith and C. J. Lightdale Review: Barrett's esophagus and the increasing role of endoluminal therapy Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 121 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Yousef, C. Cardwell, M. M. Cantwell, K. Galway, B. T. Johnston, and L. Murray The Incidence of Esophageal Cancer and High-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis Am. J. Epidemiol., August 1, 2008; 168(3): 237 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A L D'Souza Ageing and the gut Postgrad. Med. J., January 1, 2007; 83(975): 44 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Keswani, A. Noffsinger, I. Waxman, and M. Bissonnette Clinical Use of p53 in Barrett's Esophagus. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1243 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Irwin Chronic Cough Due to Gastroesophageal Reflux Disease: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 80S - 94S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kent, P. Korn, J. L. Port, P. C. Lee, N. K. Altorki, and R. J. Korst Cost Effectiveness of Chest Computed Tomography After Lung Cancer Resection: A Decision Analysis Model Ann. Thorac. Surg., October 1, 2005; 80(4): 1215 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Dellon and N. J. Shaheen Does Screening for Barrett's Esophagus and Adenocarcinoma of the Esophagus Prolong Survival? J. Clin. Oncol., July 10, 2005; 23(20): 4478 - 4482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Lagergren Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut, March 1, 2005; 54(suppl_1): i1 - i5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Sharma and E I Sidorenko Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut, March 1, 2005; 54(suppl_1): i27 - i32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N J Shaheen, J M Inadomi, B F Overholt, and P Sharma What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis Gut, December 1, 2004; 53(12): 1736 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Greenberger and P. Sharma Update in Gastroenterology and Hepatology Ann Intern Med, September 7, 2004; 141(5): 374 - 380. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Chang and D. A. Katzka Gastroesophageal Reflux Disease, Barrett Esophagus, and Esophageal Adenocarcinoma Arch Intern Med, July 26, 2004; 164(14): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hur, N. S. Nishioka, and G. S. Gazelle Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus J Natl Cancer Inst, February 18, 2004; 96(4): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Aithal, R Charnley, R F A Logan, P Moayyedi, and I D Penman JournalScan Gut, August 1, 2003; 52(8): 1219 - 1219. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Spechler Managing Barrett's oesophagus BMJ, April 26, 2003; 326(7395): 892 - 894. [Full Text] [PDF]
|
|
|
|
 |
|
 Are Screening and Surveillance for BE in GERD Patients Cost-Effective? Journal Watch Gastroenterology, March 11, 2003; 2003(311): 6 - 6. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
